Fig. 7: Model depicting the mechanism of HAT1 loss-induced BRAFi resistance.

One of the mechanisms by which loss of HAT1 drives acquired BRAFi resistance is via IGF1R-dependent activation of MAPK signaling pathway, and the pharmacological targeting of IGF1R or ERK1/2 restores the sensitivity of melanoma cells with reduced HAT1 expression levels to BRAFi.